- Home
- IHT vs OSRH Comparison
IHT vs OSRH Comparison
Compare IHT & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | IHT | OSRH |
|---|---|---|
| Founded | 1971 | N/A |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 17.9M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | IHT | OSRH |
|---|---|---|
| Price | $1.83 | $0.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 294.1K | ★ 538.4K |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $7,600,000.00 | N/A |
| Revenue This Year | N/A | $9.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.33 | N/A |
| 52 Week Low | $0.95 | $0.30 |
| 52 Week High | $4.24 | $1.24 |
Technical Indicators
Market Signals| Indicator | IHT | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 59.96 | 60.04 |
| Support Level | $1.34 | $0.40 |
| Resistance Level | $1.90 | $0.45 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 90.00 | 69.59 |
Price Performance
Historical ComparisonAbout IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns interests in two hotels, operates and provides management services, and provides trademark license services, for two hotels. The Trust also holds an investment related to clean energy electricity generation technology and manages an option to acquire an investment in an independent boutique hotel reservation and hotel services business.
About OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.